Effects of lysine to arginine mutations in HIV-1 Vif on its expression and viral infectivity

被引:0
|
作者
Khamsri, Boonruang
Fujita, Mikako
Kamada, Kazuya
Piroozmand, Ahmad
Yamashita, Tomoki
Uchiyama, Tsuneo
Adachi, Akio
机构
[1] Univ Tokushima, Dept Virol, Inst Hlth Biosci, Grad Sch, Tokushima 7708503, Japan
[2] Naresuan Univ, Fac Med Sci, Dept Microbiol & Parasitol, Phitsanulok 65000, Thailand
关键词
HIV-1; Vif; lysine; arginine;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We previously demonstrated that the expression in cells of human immunodeficiency virus type 1 (HIV-1) Vif is maintained at low level by proteasome-degradation. We examined the contribution of 16 lysines present in Vif (NL432 clone), which is composed of 192 amino acids (aa), to its expression within cells and to viral infectivity for non-permissive cells. To this end, various lysine-arginine mutations were introduced into wild-type (wt) Vif, and the mutational effects were monitored by transfection experiments. When all the lysines were changed to arginines, the mutant Vif was expressed in cells at much higher level than wt and was much more stable. Both N-terminal (aa nos. 34 and 36) and C-terminal (aa nos. 179 and 181) lysines were found to be almost sufficient for wt property. Different from this observation, one of the lysines at aa nos. 22 and 26 was demonstrated to be essential for the virus to grow in non-permissive cells. Our results showed that there is no clear co-relationship between the expression level of HIV-1 Vif and viral infectivity.
引用
收藏
页码:679 / 683
页数:5
相关论文
共 50 条
  • [41] Antiretroviral therapy targeting HIV-1 viral infectivity factor; in silico approach
    Karau, Muriira G.
    Karau, Bundi P.
    RETROVIROLOGY, 2009, 6
  • [42] Viral Infectivity Factor: A Novel Therapeutic Strategy to Block HIV-1 Replication
    Yang, Guliang
    Xiong, Xujie
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 1047 - 1055
  • [43] Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1
    Tanaka, M
    Ueno, T
    Nakahara, T
    Sasaki, K
    Ishimoto, A
    Sakai, H
    VIROLOGY, 2003, 311 (02) : 316 - 325
  • [44] Effect of partial inhibition of HIV-1 polyprotein processing and maturation on viral infectivity
    Mueller, B.
    Anders, M.
    Tervo, H-M
    Keppler, O. T.
    Kraeusslich, H.-G.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A117 - A117
  • [45] Antiretroviral therapy targeting HIV-1 viral infectivity factor; in silico approach
    Muriira G Karau
    Bundi P Karau
    Retrovirology, 6
  • [46] Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals
    Fourati, Slim
    Malet, Isabelle
    Binka, Mawuena
    Boukobza, Stephanie
    Wirden, Marc
    Sayon, Sophie
    Simon, Anne
    Katlama, Christine
    Simon, Viviana
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    AIDS, 2010, 24 (15) : 2313 - 2321
  • [47] Paradigm development: Comparative and predictive 3D modeling of HIV-1 Virion Infectivity Factor (vif)
    Balaji, Seetharaaman
    Kalpana, Rangaswamy
    Shapshak, Paul
    BIOINFORMATION, 2006, 1 (08) : 290 - 309
  • [48] DNAJB8 facilitates autophagic-lysosomal degradation of viral Vif protein and restricts HIV-1 virion infectivity by rescuing APOBEC3G expression in host cells
    Chand, Kailash
    Barman, Muneesh Kumar
    Ghosh, Payel
    Mitra, Debashis
    FASEB JOURNAL, 2023, 37 (03):
  • [49] Interplay between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity
    Henderson, Gavin J.
    Lee, Sook-Kyung
    Irlbeck, David M.
    Harris, Janera
    Kline, Melissa
    Pollom, Elizabeth
    Parkin, Neil
    Swanstrom, Ronald
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (02) : 623 - 633
  • [50] Stable expression of a defective HIV-1 protease blocks infectivity.
    Unal, A
    McPhee, F
    Dauber, DS
    Craik, CS
    FASEB JOURNAL, 1996, 10 (06): : 2327 - 2327